Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Antares PharmaPulse BiosciencesOraSure TechnologiesSurmodicsIntersect ENT
SymbolNASDAQ:ATRSNASDAQ:PLSENASDAQ:OSURNASDAQ:SRDXNASDAQ:XENT
Price Information
Current Price$3.90$20.38$9.50$57.36$19.68
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.81.51.71.31.7
Analysis Score3.53.53.32.53.2
Community Score2.82.72.82.52.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.71.71.7
Earnings & Valuation Score1.90.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$5.63$43.00$17.50$69.00$25.67
% Upside from Price Target44.23% upside110.99% upside84.21% upside20.29% upside30.42% upside
Trade Information
Market Cap$674.33 million$548.61 million$720.18 million$800.46 million$659.66 million
Beta1.441.880.0411.34
Average Volume1,263,979140,7321,097,21253,091206,783
Sales & Book Value
Annual Revenue$123.86 millionN/A$154.60 million$94.86 million$109.14 million
Price / Sales5.29N/A4.428.325.95
CashflowN/AN/A$0.19 per share$0.85 per shareN/A
Price / CashN/AN/A50.7867.64N/A
Book Value$0.33 per share$1.48 per share$4.98 per share$9.63 per share$3.75 per share
Price / Book11.82N/A1.915.965.25
Profitability
Net Income$-2,030,000.00$-46,970,000.00$16.66 million$1.12 million$-42,990,000.00
EPS($0.01)($2.26)$0.13$0.13($1.37)
Trailing P/E Ratio65.01N/AN/A717.00N/A
Forward P/E Ratio16.25N/A10.56N/A
P/E GrowthN/AN/AN/A12.89N/A
Net Margins6.64%N/A-9.05%1.18%-71.96%
Return on Equity (ROE)16.48%-156.47%-3.51%1.42%-55.81%
Return on Assets (ROA)6.69%-109.75%-3.13%1.12%-40.23%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.53%N/AN/AN/A0.72%
Current Ratio2.47%5.06%8.14%4.58%11.28%
Quick Ratio2.08%5.06%7.32%4.27%10.29%
Ownership Information
Institutional Ownership Percentage39.92%11.42%98.13%87.19%84.32%
Insider Ownership Percentage5.90%49.80%1.70%7.10%3.50%
Miscellaneous
Employees18595570370406
Shares Outstanding168.16 million26.09 million71.95 million13.76 million33.02 million
Next Earnings Date5/4/2021 (Estimated)5/10/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Zacks: Analysts Expect Intersect ENT, Inc. (NASDAQ:XENT) Will Announce Quarterly Sales of $23.30 MillionZacks: Analysts Expect Intersect ENT, Inc. (NASDAQ:XENT) Will Announce Quarterly Sales of $23.30 Million
americanbankingnews.com - April 12 at 3:46 AM
 Analysts Anticipate Intersect ENT, Inc. (NASDAQ:XENT) to Announce -$0.42 Earnings Per Share Analysts Anticipate Intersect ENT, Inc. (NASDAQ:XENT) to Announce -$0.42 Earnings Per Share
americanbankingnews.com - April 10 at 4:20 AM
Intersect ENT (XENT) Down 5.1% Since Last Earnings Report: Can It Rebound?Intersect ENT (XENT) Down 5.1% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - April 8 at 12:52 PM
Intersect ENT Announces Changes to its Board of DirectorsIntersect ENT Announces Changes to its Board of Directors
finance.yahoo.com - April 5 at 7:38 PM
Intersect ENT, Inc. (NASDAQ:XENT) Receives Consensus Recommendation of "Hold" from BrokeragesIntersect ENT, Inc. (NASDAQ:XENT) Receives Consensus Recommendation of "Hold" from Brokerages
americanbankingnews.com - April 4 at 2:28 AM
Noteworthy Thursday Option Activity: XENT, BA, WSMNoteworthy Thursday Option Activity: XENT, BA, WSM
nasdaq.com - March 19 at 2:44 PM
Dr. Neil Hattangadi Joins Intersect ENT’s Board of DirectorsDr. Neil Hattangadi Joins Intersect ENT’s Board of Directors
finance.yahoo.com - March 11 at 8:52 PM
Intersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues TopIntersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues Top
nasdaq.com - March 11 at 8:37 AM
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare ConferenceIntersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 10 at 12:22 PM
Intersect ENT Dips 4% On Wider-Than-Expected 4Q Loss, Beats On RevenuesIntersect ENT Dips 4% On Wider-Than-Expected 4Q Loss, Beats On Revenues
finance.yahoo.com - March 10 at 7:21 AM
Intersect ENT posts mixed bag Q4Intersect ENT posts mixed bag Q4
massdevice.com - March 9 at 1:47 PM
Intersect ENT: Q4 Earnings SnapshotIntersect ENT: Q4 Earnings Snapshot
sfchronicle.com - March 9 at 8:47 AM
Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial ResultsIntersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 9 at 8:47 AM
A Preview Of Intersect ENTs EarningsA Preview Of Intersect ENT's Earnings
finance.yahoo.com - March 8 at 1:59 PM
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage AdjudicCMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudic
us.acrofan.com - March 8 at 8:58 AM
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage AdjudicationCMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
finance.yahoo.com - March 8 at 8:58 AM
Temporary changes proposed for safety at three US Highway 14 intersectionsTemporary changes proposed for safety at three US Highway 14 intersections
news.yahoo.com - March 7 at 8:48 AM
Why Earnings Season Could Be Great for Intersect ENT (XENT)Why Earnings Season Could Be Great for Intersect ENT (XENT)
finance.yahoo.com - March 5 at 2:43 PM
What Does Intersect ENT, Inc.s (NASDAQ:XENT) Share Price Indicate?What Does Intersect ENT, Inc.'s (NASDAQ:XENT) Share Price Indicate?
finance.yahoo.com - March 3 at 2:40 PM
Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial ResultsIntersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 23 at 8:20 PM
Intersect ENTs (XENT) SDS With PROPEL Mini Now in U.S.Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
nasdaq.com - February 16 at 12:18 AM
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL ® Mini Sinus ImplantIntersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL ® Mini Sinus Implant
businesswire.com - February 11 at 8:33 AM
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus ImplantIntersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant
finance.yahoo.com - February 11 at 8:33 AM
Intersect ENT to Participate in Upcoming Investor ConferencesIntersect ENT to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 1 at 7:31 PM
Does Intersect ENTs (NASDAQ:XENT) Share Price Gain of 47% Match Its Business Performance?Does Intersect ENT's (NASDAQ:XENT) Share Price Gain of 47% Match Its Business Performance?
finance.yahoo.com - January 26 at 2:44 PM
DateCompanyBrokerageAction
10/1/2020Antares PharmaRaymond JamesReiterated Rating
8/10/2020Antares PharmaHC WainwrightReiterated Rating
6/21/2020Antares PharmaPiper SandlerReiterated Rating
6/21/2020Antares PharmaLADENBURG THALM/SH SHReiterated Rating
2/25/2019Antares PharmaCowenInitiated Coverage
11/6/2018Antares PharmaJefferies Financial GroupBoost Price Target
8/17/2018Antares PharmaPiper Jaffray CompaniesReiterated Rating
3/17/2021Pulse BiosciencesMaxim GroupInitiated Coverage
3/2/2021OraSure TechnologiesCitigroupLower Price Target
8/21/2020OraSure TechnologiesEvercore ISIInitiated Coverage
8/10/2020OraSure TechnologiesJPMorgan Chase & Co.Initiated Coverage
6/25/2020OraSure TechnologiesLake Street CapitalInitiated Coverage
4/21/2020OraSure TechnologiesStephensInitiated Coverage
11/11/2019OraSure TechnologiesCanaccord GenuityReiterated Rating
2/10/2021SurmodicsBarrington ResearchBoost Price Target
2/5/2021SurmodicsNeedham & Company LLCReiterated Rating
3/16/2021Intersect ENTSVB LeerinkBoost Price Target
11/19/2020Intersect ENTBTIG ResearchUpgrade
8/7/2020Intersect ENTGuggenheimUpgrade
8/4/2020Intersect ENTOppenheimerReiterated Rating
4/15/2020Intersect ENTBank of AmericaDowngrade
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.